Online, on-demand market research connecting you to the right healthcare stakeholders.
June 15, 2020
While five key factors improve, estimates on pandemic’s continued impact more than doubled;
20% say their mental health has suffered; only 34% will take an on-site pharma rep meeting before 2021
WATERTOWN MA June 15, 2020—The novel coronavirus (COVID-19)’s impact on the US will last more than twice as long as previously estimated by frontline physicians in April, who are now anticipating August 2021 before a return to normalcy. Despite substantially increased levels of system preparedness, fewer frontline physicians—24%, down from 30% in April—believe that the US can ‘flatten the curve’. Data are from the fifth report on US frontline COVID-19 treating physicians conducted and sourced by InCrowd, the pioneer for real-time, high-quality primary market intelligence for the life science industry.
“Physicians’ new, 14-month expectation for a return to normal in the US is similar to what we recently observed with our high-need patient data,” said Daniel S. Fitzgerald, CEO and president of InCrowd. “There seems to be an acceptance of a new normal—at least until there’s a vaccine. Unfortunately, we’re also seeing the toll this is taking on those on the frontlines, with 20% reporting that their mental health has seriously suffered and 35% still concerned over job security due to COVID-19. We’ll continue to monitor this strain on treating physicians.”
Five important parameters of healthcare system capacity showed significant or substantial improvement in InCrowd’s latest Wave 5 frontline treaters data:
At the same time, only 19% of frontline COVID-19 treating physicians believe that the US is taking appropriate action, less than half that for governments outside of the US (44%). Nearly a quarter of respondents reported an uptick in cases since restrictions have eased in the past few weeks. Two-thirds believed that when re-opening occurs, everyone will need to continue with universal precautions, including improved hygiene and limits on facility capacity, until there is a vaccine.
Respondents also envisioned change to other standard office practices. Just 36% said they’d consider virtual meetings with pharma sales reps within the next 30 days. Just one-in-three (34%) would be willing to take a meeting in-person before 2021.
InCrowd’s Wave 5 also detailed new treatment strategies, concern on testing accuracy, and the personal toll that continued COVID-19 care exacts.
InCrowd’s Wave 5 COVID-19 frontline treating physicians’ report included the perceptions of n=204 US physicians including emergency medicine and critical care specialists (n=82), primary care physicians (n=62), and pediatricians (n=60), each of whom is treating 20 or more unique patients for flu-like symptoms. The 10-minute MicroSurvey for Wave 5 fielded May 29-31, 2020. For more information download the full Wave 5 report.
July 2, 2020
June 15, 2020
We’d love to show you how physician answers are collected quickly, exceed traditional market research standards, and provide actionable insights.
Our sales team is standing by to help you customize the right program for your business.